Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06846268 | Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer | PHASE2 | RECRUITING | 20 | — | — | Apr 14, 2025 | Dec 31, 2027 | Jul 25, 2025 | 1 | Singapore |
MPR is defined as less than or equal to 10% of residual viable tumour in the surgical specimen.
| Arm | Type | Description |
|---|---|---|
| ADG126 in combination with pembrolizumab | EXPERIMENTAL | ADG 126 will be administered with Pembrolizumab on Day 1 and Day 22 or Pembrolizumab on Day 22 alone depending on the dose level. |
| Name | Type | Description |
|---|---|---|
| ADG126 | DRUG | Administered via intravenous infusion on Day 1 only (Q6W) or Day 1 and Day 22 (Q3W). |
| Pembrolizumab | DRUG | Administered via intravenous infusion on Day 1 and Day 22. |
Inclusion Criteria: 1. Willing and able to provide written informed consent for the trial. 2. Be ≥ 21 years of age on the date of signing informed consent. 3. ECOG performance status of 0 or 1. 4. Histologically confirmed colorectal adenocarcinoma. Rectal cancers allowed if the treatment plan was u...